Bessemer Group Inc. Sells 27,711 Shares of Hologic, Inc. (NASDAQ:HOLX)

Bessemer Group Inc. cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 57.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,946 shares of the medical equipment provider's stock after selling 27,711 shares during the quarter. Bessemer Group Inc.'s holdings in Hologic were worth $1,294,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC lifted its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Dark Forest Capital Management LP raised its holdings in Hologic by 7.9% during the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after acquiring an additional 223 shares in the last quarter. Baker Avenue Asset Management LP raised its holdings in Hologic by 0.5% during the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after acquiring an additional 225 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the last quarter. Finally, Integrated Advisors Network LLC grew its stake in Hologic by 5.4% in the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after purchasing an additional 289 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on HOLX shares. Evercore ISI dropped their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Raymond James Financial reaffirmed an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Stephens decreased their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Royal Bank Of Canada lowered their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Finally, Citigroup cut their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Hologic presently has a consensus rating of "Hold" and a consensus target price of $77.42.

Hologic Stock Performance

NASDAQ HOLX traded down $0.03 on Wednesday, reaching $65.30. The stock had a trading volume of 2,281,368 shares, compared to its average volume of 2,373,306. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The company has a market cap of $14.55 billion, a P/E ratio of 27.55, a price-to-earnings-growth ratio of 2.39 and a beta of 0.55. The firm has a fifty day moving average of $60.45 and a two-hundred day moving average of $63.86. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company posted $1.03 earnings per share. Hologic's revenue was down 1.2% compared to the same quarter last year. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director owned 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.